

7 Literaturverzeichnis

Adamczak M, Zeier M, Dikow R, Ritz E. (2002): Kidney and hypertension. *Kidney Int. Suppl.* **80**, 62-67

Ahn K, Beningo K, Olds G, Hupe D. (1992): The endothelin-converting enzyme from human umbilical vein is a membrane-bound metalloprotease similar to that from bovine aortic endothelial cells. *Proc. Natl. Acad. Sci.* **89**, 8606-8610

Alexander B, Cockrell K, Rinewalt N, Herrington J, Granger J. (2001): Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. *Am. J. Physiol.* **280**, R1388-R1392

Arai H, Hori S, Aramori I (1990): Cloning and expression of a DNA encoding an endothelin receptor. *Nature.* **348**, 730-732

Bakris G et al., (1997): Role of vasopressin in essential hypertension: racial differences. *J. Hypertens.* **15**, 545-550

Barton M, Shaw S, D'Uscio LV, Moreau P, Luscher TF. (1997): ANG II increases vascular and renal Endothelin-1 and functional Endothelin convertin enzyme activity in vivo: role of ETA receptors for Endothelin regulation. *Biochem. Biophys. Res. Commun.* 861-865

Barton M, Luscher T. (1999): Endothelin antagonists for hypertension and renal disease. *Curr Opin Nephrol Hypertens* **8**, 549-556

Barton M, Carmona R, Ortmann J, Krieger J, Traupe T. (2003) Obesity-associated activation of angiotensin and endothelin in cardiovascular system. *Int. J. of Biochemistry & Cell Biology* **35**, 826-837

Benigni A, Perico N, Remuzzi G. (2001): Research on renal endothelin in proteinurie nephropathie dictates novel strategie sto prevent progression. *Curr Opin Nephrol Hypertens.* **10**(1), 1-6

Ben-Ishay D, Saliternik R, Welner A. (1972): Separation of two strains of rats with inbred dissimilar sensitivity to DOCA-salt hypertension. *Experientia*. **28**, 1321-1322

Ben-Ishay D, Yagil Y. (1994): The Sabra hypertension-prone and -resistant strains. In: Ganten D, de Jong W, eds. *Experimental and Genetic Models of Hypertension*. Amsterdam, Netherlands: Elsevier Science BV, 272-299

Bird E, Walron T.L, Dorso R, Asaad M. (1993): Effects of Endothelin receptor antagonist BQ-123 on initial and delayed vascular responses induced by ET-1 in conscious, normotensive rats. *J. Cardiovasc. Pharmacol.* **22**, 69-73

Bottig R.M, Vane J.R. (1990): Endothelins: potent releaser of prostacyclin and EDRF. *Pol. J. Pharmacol Pharm.* **42**, 203-218

Campese V. (1994): Salt sensitivity in hypertension: renal and cardiovascular implications *Hypertension* **23**, 2531-2550

Camussi C, Bianchi G. (1988) Genetics of essential hypertension: From the unimodal-bimodal Controversy to molecular technology. *Hypertension* **12**, 620-628

Carson P, Ziesche S, Johnson G, et al., (1999): Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. *J Card Fail* **5**, 178-187

Churchill PC, Churchill MC, Bidani AK, Griffin Ka, Picken M, Pravenec M, Kren V, St. Lezin E, Wang Jm, Wang N, Kurtz TW. (1997): Genetic susceptibility to hypertension-induced renal damage in the rat. Evidence based on kidney-specific genom transfer. *J. Clin. Invest.* **100**, 1373-1382

Clozel M, Gray G.A, Breu V, Loffler B.M, Osterwalder R. (1992): The Endothelin ETB receptor mediates both vasodilatation and vasoconstriction in vivo. *Biochem. Biophys. Res. Commun.* **186**(2), 867-873

Cooper R, Rotimi C. (1997): Hypertension in blacks. *Am J. Hypertens.* **7**, 804-812

Dahl LK, Heine M, Tassinari L. (1962): Effects of chronic excess salt ingestion: Evidence that genetic factors play an important role in the susceptibility to experimental hypertension. *J. Exp. Med.* **115**, 1173-1190

Doucet J, Gonzalez W, Michel J. (1996): Endothelin Antagonists in Salt-Dependent Hypertension Associated with Renal Insufficiency. *Journal of Cardiovascular Pharmacology* **27**, 643-651

Douglas S.A, Gellai M, Ekzekiel M, Ohlstein E.H. (1994): BQ-123, a selective Endothelin subtype A-Receptor antagonist, lowers blood pressure in different rat models of hypertension. *J. Hypertens.* **12**, 561-567

Dowhan A, Yuqiang G, Peter K et al., (2004): Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. *J Clin Invest.* **114**, 504-511

D'Uscio LV, Moreo P, Shaw S, Takase H, Barton M, Lüscher TF. (1997): Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. *Hypertension*, **29**, 435-441

Elijovich F, Laffer CL, Amador E, et al., (2001): Regulation of Plasma Endothelin by Salt in Salt-Sensitive Hypertension. *Circulation* **103**, 263-268

Elijovich F, Laffer CL. (2002): Participation of renal and circulating endothelin in salt-sensitive essential hypertension. *Journal of Human Hypertension* **16**, 459-467

Emoto N, Yanagisawa M. (1995): Endothelin-converting enzyme-2 is a membranebound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. *J. Biol. Chem.* **270**, 15262-15268

Ergul S, Parish CD, Puett D, Ergul A. (1996): Racial differences in plasma Endothelin-1 concentrations in individuals with essential hypertension. *Hypertension.* **28**, 652-655

Exner DV, Dries DL, Domanski MJ, et al., (2001): Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. *N Engl J Med.* **344**, 1351-1357

Falkner B, Kushner H. (1991): Interaction of sodium sensitivity and stress in young adults. *Hypertension.* **17**(1 Suppl.), 1162-165

Ferguson JJ. (2000): Meeting highlights: highlights of the 72nd Scientific Sessions of the American Heart Association. *Circulation.* **102**, E1-E5

Ferri et al., (1994): Urinary kallikrein and salt sensitivity in essential hypertensive males. *Kidney Int.* **46**, 780-788

Fujita K, Matsumura Y, Miyazaki Y, Hshimoto N, Takaoka M, Morimoto S. (1996): ET_A Receptor-Mediated Role of Endothelin in the Kidney of DOCA-Salt hypertensive rats. *Life Sciences.* **58** (1), pp 1-7

Gallego M, Ling B. (1996): Regulation of amiloride-sensitive Na⁺ channels by endothelin-1 in distal nephron cells. *Am. J. Physiol.* **271**, 40: F451-F460

Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yamagisawa M. (2000): Salt-sensitive hypertension in endothelin-B-deficient rats. *J Clin Invest.* **105**(7), 925-33

Giachelli C, Pilcher R, Lombardi D, Denhardt D, Alpers C, Schwartz S, Johnson R. (1994): Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. *Kidney International.* **45**, 515-524

Gill JR, Grossmann E, Goldstein DS. (1991): High urinary dopa and low urinary dopamin-to-dopa ratio in salt sensitive hypertension. *Hypertension.* **18**, 614-621

Gilmore E, Stutts M, Milgram S. (2001): Scr Family Kinase Mediate Epithelial Na⁺ Channel Inhibition by Endothelin. *J Biol Chem,* **276**, 42610-42617

Griffin KA, Churchill PC, Picken M, Webb RC, Kurtz TW, Bidani AK. (2001): Differential salt-sensitivity in the pathophogenesis of renal damage in SHR and stroke prone SHR. *Am. J. Hypertens*, **14**, 311-320

Gross V, Lippoldt A, Yagil C, Yagil Y, Luft F. (1997): Pressure Natriuresis in Salt-Sensitive and Salt-Resistant Sabra Rats. *Hypertension*. **29**, 1252-1259

Gründer S, Zagato L, Yagil C, Yagil Y, Sessard J, Rossier B. (1997): Polymorphisms in the carboxy-terminus of the epithelial sodium channel in rat models for hypertension. *Hypertension*. **15**, 173-179.

Guyton AC. (1992): Kidneys and fluids in pressure regulation. Small volume but large pressure changes. *Hypertension*. **19** (1 Suppl), I2-8.

Hall JE, Guyton AC, Brands MW. (1996): Pressure-volume regulation in hypertension. *Kidney Int Suppl*. **55**, 35-41

Hall JE, Brands MW, Shek EW. (1996) Central role of the kidney and abnormal fluid volume control in hypertension. *J. Hum. Hypertens*. **10**, 633-639

Hasegawa H, Hiki K, Sawamura T et al., (1998): Purification of a novel endothelin-converting enzyme specific for big endothelin-3. *FEBS Letters*. **428**, 304-308

Helmchen U, Wenzel UO. (1994): Benign and malignant nephrosclerosis and renovascular disease. *In Renal Pathology*. Edited by Tischer CC.: 1201

Hickey KA, Rubani GM, Paul RJ, Highsmith RF. (1985): Characterization of a coronary vasoconstrictor produced by endothelial cells. *Am J Physiol*. **248**, C550-556

Hofer B, Rohmeiss P, Diekmann F, Zart R, Vogt V, Schiller S, Bauer C, Kopenhagen K, Distler A, Gretz N. (1995): Distribution of endothelin receptor subtypes in the rat kidney. Renal and haemodynamic effects of the mixed (A/B) Endothelin receptor antagonist bosentan. *Eur. J. Clin. Chem. Clin. Biochem*. **26**(3), 470-472

Hori S, Komatsu Y, Shigemoto R et al., (1992): Distinct tissue distribution and cellular localization of two messenger ribonucleic acids encoding different subtypes of rat endothelin receptors. *Endocrinology*. **130**, 1885-1895

Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, Suga S, Nakanishi S, Imura H. (1992): Organisation, structure, chromosomal assignment, and expression of the gene encoding the human Endothelin A receptor. *J. Biol. Chem.* **267**, 18797-18804

Inou A, Yanagisawa M, Kimura S, Kasuya Y, Miyancki T, Goto K, Masaki T. (1989): The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. *Proc. Natl. Acad. Sci. USA.* **86**, 2863-2867

Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hirose M. (1993): Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II- induced hypertrophy in cultured rat cardiomyocytes. *J. Clin. Invest.* **92**, 398-403

Johson RJ, Gordon KL, Suga S, Duijvestijn AM, Griffin K, Bidani A. (1999): Renal injury and salt-sensitive hypertension after exposure to catecholamines. *Hypertension*. **34**, 515-524

Kitamura K, Tanaka T, Kato J, Eto T, Tanaka K. (1989): Regional distribution of immunoreactive endothelin in porcine tissue: abundance in inner medulla of kidney. *Biochem. Biophys. Res. Commun.* **161**, 348-352

Klag M, Whelton P, Randall L, Neaton J, Brancati L, Ford C, Shulman N, Stamler J. (1996): Blood pressure and end-stage renal disease in men. *N. Engl. J. Med.* **334**, 13-18

Köhler R, Kreutz R, Grundig A, Rothermund L, Yagil C, Yagil Y, Pries A, Hoyer J. (2001): Impaired Function of endothelial Pressure-Activated Cation Channel in Salt-Sensitive Genetic Hypertension. *J. Am. Soc. Nephrol.* **12**, 1624-1629

Kohan D. (2000): Intrarenal Endothelin-1 and Hypertension. *American Journal of Kidney Disease*. **36** (1), LIV-VI

Kojima S et al. (1992): A gender difference in the association between salt sensitivity and family history of hypertension. *Am. J. Hypertens.* **5**, 1-7

Kourembanas S, Marsden K, McQuillan P, Faller V. (1991): Hypoxia induces Endothelin gene expression and secretion in cultured human endothelium. *J. Clin. Invest.* **88**, 1034-13420

Kreutz R, Kovacevic L, Schulz A, Rothermund L, Kettler M, Paul M. (2000): Effect of high diet on spontaneous hypertension in a genetic rat model with reduced nephron number. *J Hypertension.* **18**, 777-782

Kreutz R, Paul M, Ganten D. (2000) Hypertonie. In: Gerck W, Huber C, Meinertz T, Zeidler H (eds): Die Innere Medizin. Stuttgart, 10 Aufl., Stuttgart, New York: Schattauer, Kap. **6.10**, 377-399

Kuma C, Mwangi V, Nuthulangati P, Wu H, Pullen M, Brun K, Aiyar H, Morris R.A, Naughton R, Nambi P. (1994): Cloning and characterization of a novel Endothelin receptor from *Xenopus* heart. *J. Biol. Chem.* **269**, 13414-13420

Largo R, Gomez-Garre D, Liu XH, Alonso J, Blanco J, Plaza J, Egido J. (1997): Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril. *Hypertension.* **29**, 1178-1185

Lee ME, de la Monte SM, Bloch KD, Quertermous T. (1990): Expression of the potent vasoconstrictor endothelin in the human central nervous system. *J. Clin. Invest.* **86**. 141-147

Lüscher TF, Oemar S, Boulanger M, Hahn A. (1993): Molecular and cellular biology of endothelin and its receptors Part I and Part. *J. Hypertension.* **11**, 7-11 and 121-126

Lüscher T.F, Seo B.G, Buhler F.R. (1993): Potential role of Endothelin in hypertension. Controversy on Endothelin in hypertension. *Hypertension*. **21**, 752-757

Luft FC [Cum greno salis] (1999): *Dtsch Med Wochenschr*. **124** (45), 1351-1355

Luft F. (2002): Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. *Curr. Opin. Nephrol. Hypertens*. **11**, 59-66

Marsden A, Dorfman M, Collins T, Brenner M, Orkin S, Ballermann J. (1991): Regulated expression of Endothelin: linking cellular signaling pathways to kidney disease. *Am. J. Physiol*. **261**, 117-125

Maschio G, Alberti D, Janin G, et al. (1996): Effect of the angiotnsin-converting-enzyme inhibitor benazepril on the progression of cronica renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. *N. Engl. J. Med*. **334**, 939-945

Masaki T, Yanagisawa M, Gotot K. (1992): Physiology and pharmacology of endothelins. *Med. Res. Rev*. **12**(4), 391-421

Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Opgenorth T, Takaoka M. (1999): Different Contributions of Endothelin-A and Endothelin-B Receptors in the Pathogenesis of Desoxycorticosterone Acetat-Salt-Induced Hypertension in Rats. *Hypertension*. **33**, 759-765.

Matsumoto H, Suzuki N, Ondas H, Fulindo M. (1989): Abundance of Endothelin-3 in rat intestine, pituitary gland and brain. *Biochem. Biophys. Res. Commun*. **164**, 74-80

Murray K, Thompson SD, Glass DN. (1997) Pathogenesis of juvenile chronic arthritis: genetic and environmental Division of Rheumatology. *Arch Dis Child*. **77**(6), 530-534

Ohuchi T, Yangagisawa M, Gariepy CE (2000): Renal tubular effects of endothelin-B receptor signaling: its role in cardiovascular homeostasis and extracellular volume regulation. *Curr. Opin. Nephrol. Hypertens.* **9**, 435-439

Oldenberg A, Franzen A, Heinegard D. (1986): Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. *Proc Natl Acad Sci USA.* 8819-8823

Orth S, Ritz E. (1998): The Nephrotic Syndrome. *The New England Journal of Medicine.* **17**, 1202-1211

Parrinello G, Scaglione R, Pinto A, Corrao S, Cecala S, Di-Silvestre G, Amato P, Licata A, Licata G. (1996): Central obesity and hypertension: The role of plasma endothelin. *Am J Hypertens.* **9**, 1186-1191

Pollock DM (2000): Renal endothelin in hypertension. *Curr. Opin. Nephrol. Hypertens.* **9**, 157-164

Rapp JP. (2000): Genetic analysis of inherited hypertension in the rat. *Physiol Rev.* **80**(1), 135-172

Rapp JP, Dene H. (1985): Development and characteristics of inbred strains of Dahl salt-sensitive and salt-resistant rats. *Hypertension.* **7**, 340-349

Rees D, Ben-Ishay D, Moncada S. (1996): Nitric oxide and the regulation of blood pressure in the hypertension-prone and hypertension-resistant Sabra rat. *Hypertension.* **28**, 367-371

van Rossum CT, van de Mheenlt, Witteman JCM, Hofman A, Maerbach JP, Grobbee DE. (2000): Prevalence, treatment and control of hypertension by sociodemographic factors among the Dutch elderly. *Hypertension.* **35**, 814-821

Rossi G. P, Sacchetto A, Cesari M, Pessina A. (1999): Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. *Cardiovascular Research*. **43**, 300-307

Rothermund L, Lucker S, Kossmehl P, Paul M, Kreutz R. (2001): Renal Endothelin ETA/ETB Receptor Imbalance Differentiates Salt-Sensitive From Salt-Resistant Spontaneous Hypertension. *Hypertension*. **37**, 275-280

Rothermund L, Pinto Y, Vetter R, Herfort N, Kossmehl P, Neumayer H-H, Paul M, Kreutz R. (2001): Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasmic reticulum Ca²⁺ handling in hypertensive transgenic rats overexpressing the Ren2 gene. *J Hypertension*. **19**, 1465-1472

Rothermund L, Cho J, Leggewie S, Schwarz A, Bauer C, Paul M, Neumayer H, Schuppan D, Hofer B. (2000): Activation of the hepatic endothelin-system in rats with biliary liver fibrosis. *J. Cardiovasc. Pharmacol.* **36**(5 Suppl. 1), 270-273

Rothermund L, Cho J, Leggewie S, Schwarz A, Thöne-Reinecke C, Cho J, Bauer C, Paul M, Neumayer H, Schuppan D, Hofer B. (2000): Regulation of the hepatic Endothelin system in advanced biliary fibrosis in rats. *Clin. Chem. Lab. Med.* **38**(6), 507-512

Rothermund L, Pinto Y, Hofer B, Vetter R, Leggewie S, Kossmehl P, Orzechowski H.-D, Kreutz R, Paul M. (2000): Cardiac Endothelin System Impairs Left Ventricular Function in Renin-Dependent Hypertension via Decreased Sarcoplasmic Reticulum Ca²⁺ Uptake. *Circulation*. **102**, 1582-1588

Rothermund L, Paul M. (1998): The role of endothelin in hypertension
Curr Opin Nephrol Hypertens. **7**, 451-456

Ruggenti P, Perna A, Gherardi G, et al. (2000): Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury *Am. J. Kidney Dis.* **35**, 1155-1165

Ruggeneti P, Perna A, Gherardi G, Garini G, Zocalli C, Savadori M, Scolari F, Schena F, Remuzzi G. (1999): Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet*. **354**, 359-364

Sakurai Y, Yanagisawa M, Masaki T. (1996): Molecular characterization of endothelin receptors. *Trends Pharmacol Sci*. **13**, 103-108

Schiffrin E. L. (1999): Role of Endothelin-1 in Hypertension. *Hypertension*. **34**, 876-881

Schiffrin E.L, Deng L.Y, Sventek P, Day R. (1997): Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. *J. Hypertense*. **15**, 57-63

Schiffrin E, Sventek P, Li JS, Turgeon A, Reudelhuber T. (1995): Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. *Br J Pharmacol*. **115**, 1377-81

Simon M.S., Dunn M.J. (1993): Renal actions of endothelin peptides. *Curr. Opin. Nephrol. Hypertens*. **2**(1), 51-60

Stamler J, Rose G, Elliot P. (1991): Findings of the International Cooperative INTERSALT study. *Hypertension*. **17**, 17-19

Suga SI, Phillips MI, Ray PE, Raleigh JA, Vio CP, Kim YG, Mazzali M, Gordon KL, Hughes J, Johnson RJ. (2001): Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. *Am J Physiol Renal Physiol*. **281**(4), F620-9

Tekeda N, Breyer M.D, Noland T. D, Homma T, Hoover R.L, Inagami T, Kon v. (1992): Endothelin-1 receptor antagonist: effects on Endothelin- and cyclosporine-treated mesangial cells. *Kidney Int*. **41**(6), 1713-1719

Terada Y, Tomita K, Nonoguchi H, Marumo F. (1992): Different localization of two types of Endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. *J. Clin. Invest.* **90**, 107-112

Thomas SE, Lombardi D, Giachelli C, Bohle A, Johnson R. (1998): Osteopontin expression, tubulointestinal disease, and essential hypertension. *Am. J. Hypertens.* **11**, 954-961

Tracy RE. (1992): Blood pressure related separately to parenchymal fibrosis in vasculopathy in the kidney. *Am. J. Kidney Dis.* **20**, 124-131

Tracy RE, Berenson G, Wattigney W, Barrett TJ. (1990): The evolution of begin arterionephrosclerosis from age 6 to 70 years. *Am. J. Pathol.* **136**, 429-439

Traupe T, Ortman J, Munter K, Barton M. (2003) Endothelial therapy of atherosclerosis and its risk factors. *Curr Vasc Pharmacol.* Jun; **1**(2):111-121

Valdenaire O, Rohrbacher E, Geneviève Mattei M. (1995): Organisation of the gene encoding the human endothelin-converting enzyme (ECE-1). *J. Biol. Chem.* Vol **270**, 29794-29798

Warner T.D, Alock G.H, Mickley J, Corder R, Vane J.R. (1993): Comparative studies with the Endothelin receptor antagonist BQ 123 and PD 142893 indicates at least three endothelon receptors. *J. Cardiovasc. Pharmacol.* **22**(Suppl. 8), 117-120

Weinberger HM, Fineberg NS. (1991): Sodium and volume sensitivity of blood pressure: age and pressure change over the time. *Hypertension.* **18**, 67-71

Weinberger M. (1996): Salt sensitivity of blood pressure in humans. *Hypertension.* **27**, 481-490

Wesson D. (2001): Hypertension and the kidney. Sowohl die essentielle als auch die sekundäre Hypertonie können durch eine verminderte Nierendurchblutung mit

Aktivierung des Renin-Angiotensin-Systems zu einer renalen Fixierung des Bluthochdrucks führen. *Current Hypertension Reports*. **3**, 511-516

Wright E, Fozard R. (1988): Regional vasodilatation is a prominent feature of the haemodynamic response to endothelin in anesthetized spontaneously hypertensive rats. *Eur. J. Pharmacol.* **155**, 201-203

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. (1988): A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. **332**, 411-415.

Yagil C, Sapojnikov M, Katni G, Ilan Z, Zangen S, Rosenmann E, Yagil Y. (2002): Proteinuria and glomerulosclerosis in the Sabra genetic rat model of salt susceptibility. *Physiol. Genomics*. **9**, 167-178

Yagil Y, Yagil C. (2000): The lack of a modulating effect of non-genetic factors (age, Gonads and maternal environment) on the phenotypic expression of the salt-susceptibility genes in the Sabra rat model of hypertension. *J Hypertension*. **18**, 1393-1399

Yagil C, Sapojnikov M, Kreutz R, Zürcher H, Ganten D, Yagil Y. (1999): Role of Chromosome X in the Sabra Rat Model of Salt-Sensitive Hypertension. *Hypertension*. **33** [part II], 261-265

Yagil Y, Yagil C. (1998): Genetic basis of salt-susceptibility in the Sabra rat model of hypertension. *Kidney Int.* Vol. **53** pp. 1493-1500

Yagil C, Sapojnikov M, Kreutz R, Katni G, Lindpaintner K, Ganten D, Yagi Y. (1998): Salt Susceptibility Maps to Chromosomes 1 and 17 With Sex Specificity in the Sabra Rat Model of Hypertension. *Hypertension*. **31**, 119-124

Yagil Y, Yagil C. (1998): Does the Sabra hypertension-prone rat represent a model of salt or mineralocorticoid sensitivity? *Hypertension*. **16**, 1481-1484

Yagil C, Katni G, Rubattu S, Stolpe C, Kreutz R, Lindpainter K, Ganten D, Ben-Ishay D, Yagol Y. (1996): Development, genotype and phenotype of a new colony of the Sabra hypertension prone (SBH/y) and resistant (SBN/y) rat model of salt sensitivity and resistance. *Hypertension*. **14**, 1175-1182

Yagil Y, Mekler J, Popovtzer M, Ben-Ishay D. (1986): Sodium handling by the Sabra hypertension prone (SBH) and resistant (SBN) rats. *Pflügers Arch*. **407**, 547-551

Yancy CW. (2001) Heart failure in blacks: etiologic and epidemiologic differences. *Curr. Cardiol. Rep.* **3**, 191-197

Yancy CW, Fowler MB, Colucci WS, et al. (2001): Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. *N Engl J Med*. **344**, 1358-1365

Yokokawa K, Tahara H, Kohno M et al. (1991): Hypertension associate with Endothelin-secreting malignant hemangioendothelioma. *Ann Int Med*. **114**, 213-215

Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Geiyo F. (2001): Expression, roles, receptors, and regulation of osteopontin in the kidney. *Kidney International* **60**, 1645-1657

Xu D, Emoto N, Giagid A, Slaughter C, Kaw S, de Wit D, Yanagisawa M. (1994): A membrane bound metalloprotease that catalyses the proteolytic activation of big Endothelin-1. *Cell* **78**, 473-485

Zucchelli P, Zuccala A, Bughi M, Fusaroli M, Sasdelli M, Stalone C, SannaG, Gaggi R. (1992): Long-term comparison between captopril and nifedipine in progression of renal insufficiency. *Kidney Int*. **42**(2), 452-458